Unicycive granted FDA review for kidney disease drug (UNCY)

Unicycive Therapeutics (UNCY) announced on Thursday that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for its kidney disease therapy oxylanthanum carbonate (OLC). In late June, the FDA declined to approve the oral phosphate ...